Cannabis Science Inc. (OTC:CBIS) has announced that the company has signed a Collaborative Drug Deal with IGXBio and its GenePro, which is a DNA-based immunotherapeutic that has received the green signal from the FDA IND to start with the human trials. The two medical research companies are expected to develop a joint protocol to demonstrate the synergistic effects of their own respective drugs that can have an impact on HIV.
In a statement issued by James Laufenberg, CEO of IGXBio, he expressed his excitement about the collaboration with Cannabis Science, which he acclaims to be based on the same values as that of their own in serving to meet the unmet needs of HIV positives patients.
The GenePro ® technology has been on at least 150 covers of many scientific journals and it intends to produce the technology on a wide scale. Mr. Laufenberg did point out though that it will be a big undertaking, since they had to conduct pre-clinical trials through $21 million of funds being granted. This ends the company’s cooperation with Cannabis Science to serve to create new medicinal products for the purpose of clinical development and commercialization using the technology in the first and second phase of the trial.
Roscoe M. Moore, DVM, MPH, Ph.D., DSc., Former Asst. US Surgeon General, Cannabis Science Special Senior Advisor, and Member of the Company's Scientific Advisory Board, explained that risks of inflammation can possibly be lowered along with HIV viral replication, which can greatly help in health and extend the lives of HIV patients. That can happen with the GenePro technology, partnered by CS-TATI-1.
In addition, Mr. Raymond C. Dabney, President, CEO, and Co-Founder of Cannabis Science, for his part says that collaboration between the two medical research companies will help to provide new discoveries into the role of inflammation vaccination of HIV, which serves as a very first critical step in optimizing effective treatments in various settings. The studies will also serve to provide scientific evaluations to the GenePro Technology to demonstrate the enhanced potential of therapeutic vaccination.
While the development is welcomed, it is still early days to ascertain if its drive will prove to be a success, despite the many bullish assessments from the two partners involved in this deal, not least because diseases are developing resistance at a relatively faster rate than the pace of development of new drugs, especially for HIV Aids.
Cannabis Science stock price ended the day at $0.0305, a massive rise of 1.67% from the previous day.
No comments:
Post a Comment